Ackman then pulled out the activist-investor playbook to pressure Allergan to accept an offer from Valeant. He wrote nasty letters describing Allergan's "incredibly inappropriate" behavior as it sought to fend off the takeover by a company that was known for slashing research-and-development spending and jacking up drug prices.